Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    The WHO guideline on GLP-1 drugs for obesity

    On 1 December 2025 the World Health Organization issued its first guideline on GLP-1 medicines for obesity, covering liraglutide, semaglutide and tirzepatide.[1][2] It conditionally recommends that adults, excluding pregnant women, may use them for long-term treatment, alongside behavioural support.[3] WHO calls the advice conditional because long-term evidence, costs and health-system readiness are limited, and projects the drugs will reach fewer than 10% of those who could benefit by 2030.[4][5]

    Editor reviewedStrict sourcingUpdated Explainer13 claims · 100% primaryGLP-1 and metabolic medicine, Nutrition and fitness, Health and medicine

    The world-health-organization issued its first guideline on GLP-1 medicines for treating obesity on 1 December 2025.[1] It treats obesity as a chronic, relapsing disease that needs comprehensive, lifelong care rather than medication alone.[6] WHO says obesity affects more than 1 billion people and was linked to 3.7 million deaths in 2024.[7]

    This page is not medical advice. Decisions about weight-loss medicines should be made with a doctor.

    What it recommends

    The guideline makes two conditional recommendations. First, GLP-1 therapies may be used by adults, excluding pregnant women, for the long-term treatment of obesity. Second, intensive behavioural interventions on diet and physical activity may be offered to adults prescribed them; WHO rates the evidence for this as low-certainty.[3]

    It covers three medicines: liraglutide, semaglutide and tirzepatide. WHO defines adult obesity as a body mass index of 30 or higher.[2] For how the drugs work, see how GLP-1 drugs work.

    Why the advice is conditional

    WHO says the recommendation is conditional. It cites limited data on long-term efficacy and safety, on maintenance and discontinuation, their current costs, health systems’ preparedness and possible effects on equity.[4] Those open questions are discussed in the GLP-1 long-term use debate.

    Access and cost

    WHO projects that even with rapid expansion in production, GLP-1 therapies will reach fewer than 10% of those who could benefit by 2030.[5] The guideline asks the global community to consider pooled procurement, tiered pricing and voluntary licensing. WHO said it would work during 2026 on a framework to reach people with the highest need first.[8] In September 2025 WHO had already added GLP-1 therapies to its Essential Medicines List for type 2 diabetes in high-risk groups.[9]

    WHO also warns that demand has fuelled falsified and substandard GLP-1 products. It says quality depends on regulated distribution and prescription by qualified providers.[10] Pricing disputes are covered in the GLP-1 access and pricing debate.

    Beyond medicines

    WHO says medicines alone will not solve obesity.[6] It calls for a strategy on three pillars: healthier environments through population-level policies, targeted screening and early intervention for people at high risk, and lifelong, person-centred care.[11] WHO projects that without decisive action the number of people with obesity will double by 2030, and it predicts that the global economic cost of obesity will reach US$3 trillion a year by 2030.[12] WHO developed the guideline at the request of member states and says it will update it regularly as evidence emerges.[13] See also obesity as a disease.

    World Health Organization (WHO)

    The UN agency for health: how WHO is governed and funded, the US withdrawal that took effect in January 2026, and the Pandemic Agreement's unfinished annex.

    More in GLP-1 and metabolic medicine

    Developing in Health

    Go deeper

    Questions readers ask

    What does the WHO guideline recommend?

    Two conditional recommendations. GLP-1 therapies may be used by adults, excluding pregnant women, for long-term obesity treatment, and intensive behavioural support on diet and exercise may be offered to people prescribed them.[3]

    Why are the recommendations conditional?

    WHO cites limited data on long-term efficacy and safety, on maintenance and stopping treatment, current costs, health-system preparedness and possible effects on equity.[4]

    Which drugs does the guideline cover?

    Liraglutide, semaglutide and tirzepatide, for long-term treatment of obesity in adults, which WHO defines as a BMI of 30 or higher.[2]

    Does WHO say drugs alone can solve obesity?

    No. The guideline says medicines alone will not solve the problem and calls for healthier environments, early help for people at high risk and lifelong care.[6][11]

    How many people will be able to get GLP-1 drugs?

    WHO projects that even with rapid expansion in production, GLP-1 therapies will reach fewer than 10% of those who could benefit by 2030.[5]

    Sources

    · 13 claims from 1 publisher

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      On 1 December 2025 WHO issued its first guideline on GLP-1 medicines for obesity, with conditional recommendations that adults may use them for long-term treatment alongside behavioural interventions. confirmedas of 2025-12-01

    2. [2]

      The guideline covers three medicines for long-term obesity treatment in adults (liraglutide, semaglutide and tirzepatide), and WHO defines adult obesity as a body mass index of 30 or higher. confirmedas of 2025-12-01

    3. [3]

      The WHO guideline makes two conditional recommendations. GLP-1 therapies may be used by adults, excluding pregnant women, for the long-term treatment of obesity, and intensive behavioural interventions on diet and physical activity may be offered to adults prescribed them, based on low-certainty evidence. confirmedas of 2025-12-01

    4. [4]

      WHO says the recommendation is conditional because of limited data on long-term efficacy and safety, maintenance and discontinuation, current costs, health-system preparedness and possible effects on equity. confirmedas of 2025-12-01

    5. [5]

      WHO projects that even with expanded production, GLP-1 therapies will reach fewer than 10% of those who could benefit by 2030. confirmedas of 2025-12-01

    6. [6]

      WHO's 2025 guideline describes obesity as a chronic, relapsing disease that needs comprehensive, lifelong care rather than medication alone. confirmedas of 2025-12-01

    7. [7]

      According to WHO, obesity affects more than 1 billion people and was linked to 3.7 million deaths in 2024. confirmedas of 2025-12-01

    8. [8]

      The guideline asks the global community to consider pooled procurement, tiered pricing and voluntary licensing to widen access, and WHO said it would work during 2026 on a framework to prioritise people with the highest need. confirmedas of 2025-12-01

    9. [9]

      In September 2025 WHO added GLP-1 therapies to its Essential Medicines List for type 2 diabetes in high-risk groups. confirmedas of 2025-12-01

    10. [10]

      WHO warns that demand for GLP-1 therapies has fuelled falsified and substandard products, and says quality requires regulated distribution and prescription by qualified health care providers. confirmedas of 2025-12-01

    11. [11]

      WHO calls for a strategy on three pillars, namely healthier environments through population-level policies, targeted screening and early intervention for people at high risk, and access to lifelong, person-centred care. confirmedas of 2025-12-01

    12. [12]

      WHO projects that without decisive action the number of people with obesity will double by 2030, and separately predicts that the global economic cost of obesity will reach US$3 trillion a year by 2030. confirmedas of 2025-12-01

    13. [13]

      WHO developed the guideline at the request of member states, with evidence review and stakeholder consultation including people with lived experience, and says it will be updated regularly as evidence emerges. confirmedas of 2025-12-01

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 14, 2027.

    Cite this page

    "The WHO guideline on GLP-1 drugs for obesity." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/who-glp-1-obesity-guideline

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.